arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Pyxis Oncology, Inc.

PYXS Health Care Biotechnology: Pharmaceutical Preparations
$1.68
▼ -4.5% Today
as of Oct 23, 16:51 ET
Last 30 days -51.02% Sep 14 → Oct 23
$1.54 $2.05 $2.56 $3.06 $3.57 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$1.70
High
$1.70
Low
$1.63
Volume
$626,619
Avg Vol
$968,088
Mkt Cap
$239M
P/E (TTM)
—
Beta
—
52w High
$5.55
52w Low
$1.03
Div Yield
—
Shares Out
$63M

Recent Press Releases & News last 60 days · 14 items

Oct 2 · 11:00 PR GlobeNewswire
Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering
Sep 30 · 18:46 MT Newswires
Update: Pyxis Oncology Shares Fall After Pricing Public Offering of Common Stock, Warrants
Sep 30 · 07:58 MT Newswires
Pyxis Oncology Prices Public Offering of Common Stock, Warrants
▸ Show all 14 press releases & news Free account →

PYXS earnings at a glance

Pyxis Oncology, Inc. (PYXS) is scheduled to report earnings on Monday, November 2, 2026 — in 10 days. Analysts expect earnings per share of -$0.27, compared with -$0.35 in the same quarter last year (+23%). The options market is pricing a move of about ±15.2% after the report, a range of roughly $1.43 to $1.93 from today's $1.68. Over its last 6 reports the stock rose the next day 3 times and fell 3, moving ±7.3% on average; after the most recent report on Aug 13, 2026 it moved -5.3%. That means options currently expect more movement than PYXS has typically delivered. PYXS beat the consensus EPS estimate in 3 of its last 6 reported quarters. Implied volatility is currently 128%. The share price of $1.68 sits near its 52-week low.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$1.03
$5.55
14% of range
Avg surprise (last 6)
-1.2%
Avg reaction (last 6)
-0.8%
50% positive
Latest IV / EM
128%
EM ±15.2% · $2 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.56$-0.44$-0.31$-0.19$-0.06 Actual $-0.54Actual $-0.41Actual $-0.56Actual $-0.06Actual $-0.29Actual $-0.35Actual $-0.35Est $-0.29Actual $-0.30Est $-0.36Actual $-0.35Est $-0.36Actual $-0.29Est $-0.35Actual $-0.37Est $-0.35Actual $-0.40Est $-0.34 MarJunSepMarJunSepMar/2025Jun/2025Sep/20258KMar/2026Jun/2026
Revenue vs Net Income Revenue Net income
$-25M$-18M$-11M$-4M$3M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Thu Aug 13, 2026Jun/2026 $-0.40 $-0.34 -17.6% -13.3% -5.3% earnings
Thu May 14, 2026Mar/2026 $-0.37 $-0.35 -5.7% -5.7% -15.6% earnings
Mon Mar 23, 20268K 2026-03-23 $-0.29 $-0.35 +17.1% — -3.4% earnings
Mon Nov 3, 2025Sep/2025 $-0.35 $-0.36 +2.8% — +7.0% earnings
Thu Aug 14, 2025Jun/2025 $-0.30 $-0.36 +16.7% — +8.8% earnings
Thu May 15, 2025Mar/2025 $-0.35 $-0.29 -20.7% — +3.7% earnings
Mon Sep 30, 2024Sep 2024 $-0.35 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.29 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.06 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.56 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.41 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.54 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Mon Nov 2, 2026Sep/2026OTHER -$0.27-$0.35 +22.9%

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————$3M———
Cost of revenue————————
Gross profit————————
Operating income$-26M$-24M—$-23M$-20M$-23M—$-24M
Net income$-25M$-23M—$-22M$-18M$-21M—$-21M
EPS (diluted)$-0.40$-0.37—$-0.35$-0.30$-0.35—$-0.35

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$19M$6M$15M$9M$11M$13M$19M$12M
Inventory————————
Total current assets$37M$46M$72M$83M$100M$112M$132M$149M
Total assets$55M$64M$92M$106M$123M$136M$157M$195M
Long-term debt————————
Total liabilities$43M$33M$38M$37M$36M$33M$36M$42M
Total equity$11M$31M$53M$69M$88M$103M$121M$154M

Implied volatility — last 90 days

53%418%782%1147%1512% Jun 07 — IV 406% · EM ±56.2%Jun 08 — IV 717% · EM ±94.7%Jun 09 — IV 756% · EM ±94.7%Jun 10 — IV 811% · EM ±95.8%Jun 11 — IV 921% · EM ±101.8%Jun 12 — IV 889% · EM ±90.9%Jun 15 — IV 1234% · EM ±89.3%Jun 16 — IV 1355% · EM ±80.0%Jun 17 — IV 1512% · EM ±63.2%Jun 26 — IV 135% · EM ±25.9%Jun 29 — IV 175% · EM ±30.9%Jun 30 — IV 248% · EM ±42.6%Jul 01 — IV 221% · EM ±36.8%Jul 02 — IV 106% · EM ±17.1%Jul 03 — IV 110% · EM ±17.1%Jul 06 — IV 139% · EM ±19.3%Jul 07 — IV 204% · EM ±26.9%Jul 08 — IV 267% · EM ±33.5%Jul 09 — IV 176% · EM ±20.8%Jul 10 — IV 220% · EM ±24.3%Jul 13 — IV 196% · EM ±16.4%Jul 14 — IV 91% · EM ±6.5%Jul 15 — IV 157% · EM ±9.3%Jul 20 — IV 132% · EM ±31.1%Jul 21 — IV 77% · EM ±17.9%Jul 22 — IV 143% · EM ±32.7%Jul 23 — IV 146% · EM ±32.8%Jul 24 — IV 147% · EM ±32.6%Jul 27 — IV 131% · EM ±27.3%Jul 28 — IV 109% · EM ±22.3%Jul 29 — IV 103% · EM ±20.5%Jul 30 — IV 178% · EM ±34.8%Jul 31 — IV 113% · EM ±21.7%Aug 03 — IV 116% · EM ±20.6%Aug 04 — IV 119% · EM ±20.6%Aug 05 — IV 167% · EM ±28.0%Aug 06 — IV 251% · EM ±40.7%Aug 07 — IV 475% · EM ±74.3%Aug 10 — IV 452% · EM ±62.7%Aug 11 — IV 187% · EM ±24.6%Aug 12 — IV 308% · EM ±38.6%Aug 13 — IV 332% · EM ±39.2%Aug 14 — IV 331% · EM ±36.5%Aug 17 — IV 396% · EM ±33.1%Aug 18 — IV 439% · EM ±31.8%Aug 19 — IV 1005% · EM ±59.3%Aug 20 — IV 1074% · EM ±44.9%Aug 24 — IV 121% · EM ±25.3%Aug 25 — IV 216% · EM ±44.1%Aug 26 — IV 142% · EM ±28.4%Aug 27 — IV 138% · EM ±27.1%Aug 28 — IV 356% · EM ±68.1%Aug 31 — IV 235% · EM ±41.7%Sep 01 — IV 312% · EM ±53.8%Sep 02 — IV 343% · EM ±57.3%Sep 03 — IV 442% · EM ±71.5%Sep 04 — IV 427% · EM ±66.7%Sep 07 — IV 473% · EM ±65.6%Sep 08 — IV 222% · EM ±29.4%Sep 09 — IV 516% · EM ±64.7%Sep 10 — IV 492% · EM ±58.1%Sep 11 — IV 479% · EM ±53.0%Sep 14 — IV 611% · EM ±51.0%Sep 15 — IV 789% · EM ±57.1%Sep 16 — IV 898% · EM ±53.0%Sep 17 — IV 1299% · EM ±54.3%Sep 21 — IV 144% · EM ±30.1%Sep 22 — IV 177% · EM ±36.1%Sep 23 — IV 186% · EM ±37.3%Sep 24 — IV 149% · EM ±29.1%Sep 25 — IV 119% · EM ±22.7%Sep 28 — IV 224% · EM ±39.7%Sep 29 — IV 71% · EM ±12.3%Sep 30 — IV 53% · EM ±8.9%Oct 01 — IV 148% · EM ±24.0%Oct 02 — IV 119% · EM ±18.6%Oct 05 — IV 131% · EM ±18.2%Oct 07 — IV 99% · EM ±12.4%Oct 08 — IV 128% · EM ±15.2%

Sector peers

SLGL
Sol-Gel Technologies Ltd.
$238M $69.45+5.7%
AKBA
Akebia Therapeutics, Inc.
$241M $0.57-3.1%
SIGA
SIGA Technologies Inc.
$234M $3.120.0%
QTTB
Q32 Bio Inc.
$246M $8.65-0.2%
PRQR
ProQR Therapeutics N.V.
$230M $1.29-5.8%
IFRX
InflaRx N.V.
$252M $1.56+0.7%

PYXS earnings FAQ

When is PYXS's next earnings date?

Pyxis Oncology, Inc. is expected to report on November 2, 2026.

What is PYXS's expected move for earnings?

Options currently price a move of about ±15.2%, or $0.25 per share either way from $1.68.

How does PYXS stock usually react to earnings?

Across the last 6 reports the average next-day move was ±7.3%, up 3 times and down 3 times.

What EPS are analysts expecting from Pyxis Oncology, Inc.?

The consensus estimate is -$0.27 per share, versus -$0.35 a year ago.

What is PYXS's implied volatility?

PYXS's at-the-money implied volatility is about 128% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in